{{Rsnum
|rsid=2699887
|Gene=PIK3CA
|Chromosome=3
|position=179148620
|Orientation=minus
|GMAF=0.1488
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PIK3CA,RP11-360P21.2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 7.1 | 43.4 | 49.6
| HCB | 0.7 | 14.6 | 84.7
| JPT | 1.8 | 10.6 | 87.6
| YRI | 0.0 | 4.1 | 95.9
| ASW | 0.0 | 12.3 | 87.7
| CHB | 0.7 | 14.6 | 84.7
| CHD | 0.0 | 10.1 | 89.9
| GIH | 4.0 | 34.7 | 61.4
| LWK | 0.9 | 11.8 | 87.3
| MEX | 1.7 | 36.2 | 62.1
| MKK | 1.3 | 22.2 | 76.5
| TSI | 5.9 | 29.4 | 64.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=20447721
|Title=PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy
|OA=1
}}

{{PMID Auto
|PMID=19164214
|Title=Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
|OA=1
}}

{{PMID Auto
|PMID=22146979
|Title=Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
|OA=1
}}

{{on chip | Illumina Human 1M}}